- Morgan Stanley has upgraded Humana to overweight from equal weight citing the managed care provider's expected strong Medicare Advantage growth in 2023.
- The firm has a $549 price target (~10% upside based on Monday's close).
- Analyst Michael Ha said that Humana ( NYSE: HUM ) has greatly improved its competitive positioning and "2023 is more than just a one-year MA pricing reset but a structural enhancement to Humana’s MA benefit offering creating a value proposition that we believe should provide stronger membership growth in the coming years."
- He added that Humana ( HUM ) may see a move up from the No. 5 ranked retail Medicare Advantage prescription drug plan in terms of benefit richness to the No. 1 in 2023, though such an improvement would be unprecedented.
- Humana ( HUM ) recently raised its 2022 guidance .
For further details see:
Humana upgraded to overweight at Morgan Stanley on improved Medicare Advantage positioning